

Haematologica
HAEMATOL/2018/212217
Version 4

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients

Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav ermák, Eva Hellström-Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mdry, Ulrich Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njetoka Gredelj-imec, Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael Itzykson, Corine van Marrewijk, Nicole Blijlevens, David Bowen, and Theo de Witte
(Collaborative Groups: EUMDS Registry Participants)

Disclosures: PF: Research funding and honoraria from Amgen, Astex, Celgene, Janssen, Novartis, and Roche; ASY: honoraria and consulting fees from Amgen, Celgene/GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; EHL: research funding from Celgene; GS: research funding and honoraria from Amgen, Celgene, and Novartis, and consulting fees from Amgen, Boehringer-Ingelheim, Celgene, MSD, and Novartis; MSH: research funding from Celgene; UG: research funding and honorarium from Novartis; ASA has received honoraria and consulting fees from Hoffmann-La Roche, MSD, and Pfizer; AMA: honoraria from Alexion and BMS, and consulting fees from Celgene, Novartis, and Servier; RI: research funding and honoraria from Amgen, BMS, Celgene, Janssen, Oncoethix (now Merck MSD) and Sanofi, and consulting fees from Karyopharm, Novartis, and Otsuka; CvM: funded by the EUMDS project budget; NB: research funding from Ariad, Astellas, BMS, Celgene, MSD, Novartis, Pfizer, and Xenikos, and educational grants from Celgene, Janssen Cilag, and Novartis; TdW: research funding and honorarium from Amgen, Celgene, and Novartis, as project coordinator EUMDS. The remaining authors (LdS, SC, MH, AS, SL, JC, RS, MM, LM, KM, AT, NGS, AGB, OBR, DC, IK, and DB) declare no competing financial interests.

Contributions: Design: LdS, SC, MH, AS, SL, DB, and TDW; provision of patients, assembly of data: SC, AS, SL, PF, ASY, JC, EHL, RS, GS, MM, MSH, LM, KM, UG, AT, ASA, AMA, NGS, AGB, OBR, DC, IK, RI, CvM, DB, and TdW; statistical analysis: LdS, SC, AS, DB, and TdW; manuscript writing: all authors; nal approval: all authors.